From the Department of Pharmaceutical Oncology and; the St. Mary's Hospital, Kurume 830-8543.
From the Department of Pharmaceutical Oncology and.
J Biol Chem. 2013 Aug 30;288(35):25025-25037. doi: 10.1074/jbc.M113.472068. Epub 2013 Jul 11.
The expression of N-myc downstream-regulated gene 1 (NDRG1) was significantly correlated with tumor angiogenesis and malignant progression together with poor prognosis in gastric cancer. However, the underlying mechanism for the role of NDRG1 in the malignant progression of gastric cancer remains unknown. Here we examined whether and how NDRG1 could modulate tumor angiogenesis by human gastric cancer cells. We established NU/Cap12 and NU/Cap32 cells overexpressing NDRG1 in NUGC-3 cells, which show lower tumor angiogenesis in vivo. Compared with parental NU/Mock3, NU/Cap12, and NU/Cap32 cells: 1) induced higher tumor angiogenesis than NU/Mock3 cells accompanied by infiltration of tumor-associated macrophages in mouse dorsal air sac assay and Matrigel plug assay; 2) showed much higher expression of CXC chemokines, MMP-1, and the potent angiogenic factor VEGF-A; 3) increased the expression of the representative inflammatory cytokine, IL-1α; 4) augmented JNK phosphorylation and nuclear expression of activator protein 1 (AP-1). Further analysis demonstrated that knockdown of AP-1 (Jun and/or Fos) resulted in down-regulation of the expression of VEGF-A, CXC chemokines, and MMP-1, and also suppressed expression of IL-1α in NDRG1-overexpressing cell lines. Treatment with IL-1 receptor antagonist (IL-1ra) resulted in down-regulation of JNK and c-Jun phosphorylation, and the expression of VEGF-A, CXC chemokines, and MMP-1 in NU/Cap12 and NU/Cap32 cells. Finally, administration of IL-1ra suppressed both tumor angiogenesis and infiltration of macrophages by NU/Cap12 in vivo. Together, activation of JNK/AP-1 thus seems to promote tumor angiogenesis in relationship to NDRG1-induced inflammatory stimuli by gastric cancer cells.
N-霉酰基-D-天冬氨酸合成酶 1(NDRG1)的表达与肿瘤血管生成和恶性进展显著相关,并与胃癌的不良预后相关。然而,NDRG1 在胃癌恶性进展中的作用机制尚不清楚。在这里,我们研究了 NDRG1 是否以及如何通过人类胃癌细胞来调节肿瘤血管生成。我们在 NUGC-3 细胞中建立了过表达 NDRG1 的 NU/Cap12 和 NU/Cap32 细胞,这些细胞在体内显示出较低的肿瘤血管生成。与亲本 NU/Mock3 相比,NU/Cap12 和 NU/Cap32 细胞:1)在小鼠背部气囊测定和 Matrigel plugs 测定中诱导的肿瘤血管生成高于 NU/Mock3 细胞,伴随着肿瘤相关巨噬细胞的浸润;2)表现出更高的 CXC 趋化因子、MMP-1 和强效血管生成因子 VEGF-A 的表达;3)增加了代表炎症细胞因子 IL-1α 的表达;4)增加了 JNK 磷酸化和激活蛋白 1(AP-1)的核表达。进一步分析表明,AP-1(Jun 和/或 Fos)的敲低导致 VEGF-A、CXC 趋化因子和 MMP-1 的表达下调,并抑制了 NDRG1 过表达细胞系中 IL-1α 的表达。用白细胞介素 1 受体拮抗剂(IL-1ra)处理导致 JNK 和 c-Jun 磷酸化以及 NU/Cap12 和 NU/Cap32 细胞中 VEGF-A、CXC 趋化因子和 MMP-1 的表达下调。最后,IL-1ra 的给药抑制了 NU/Cap12 在体内的肿瘤血管生成和巨噬细胞浸润。总之,JNK/AP-1 的激活似乎通过胃癌细胞促进了与 NDRG1 诱导的炎症刺激相关的肿瘤血管生成。